AR054238A1 - Composicion farmaceutica que contiene una biguanida y un derivado de tiazolidindiona - Google Patents

Composicion farmaceutica que contiene una biguanida y un derivado de tiazolidindiona

Info

Publication number
AR054238A1
AR054238A1 AR20060100990A ARP060100990A AR054238A1 AR 054238 A1 AR054238 A1 AR 054238A1 AR 20060100990 A AR20060100990 A AR 20060100990A AR P060100990 A ARP060100990 A AR P060100990A AR 054238 A1 AR054238 A1 AR 054238A1
Authority
AR
Argentina
Prior art keywords
dosage form
derivative
component
thiazolidinedione
tiazolidindiona
Prior art date
Application number
AR20060100990A
Other languages
English (en)
Original Assignee
Andrx Labs Llc
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37073782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054238(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Andrx Labs Llc, Takeda Pharmaceutical filed Critical Andrx Labs Llc
Publication of AR054238A1 publication Critical patent/AR054238A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Forma de dosificacion farmacéutica que comprende un componente de liberacion controlada que comprende una droga antihiperglucémica en combinacion con un segundo componente que comprende un derivado de tiazolidindiona. Reivindicacion 1: Una forma de dosificacion farmacéutica que contiene una primera y una segunda droga activa, caracterizada porque dicha forma de dosificacion comprende: (a) un nucleo de liberacion controlada que comprende una droga antihiperglucémica y al menos un excipiente aceptable para uso farmacéutico; y (b) un derivado de tiazolidindiona de liberacion inmediata que contiene un componente que comprende un derivado de tiazolidindiona y un aglutinante de baja viscosidad soluble en agua donde no menos del 85% de la tiazolidindiona se libera a partir de la forma de dosificacion dentro de los 45 minutos cuando se la evalua de acuerdo con la Farmacopea de los EE.UU. (USP) 26, con el Aparato 1 a 100rpm, 37 degree C y 900 ml de solucion amortiguadora de KCl 0,3 M-HCL, pH 2,0.
AR20060100990A 2005-03-30 2006-03-15 Composicion farmaceutica que contiene una biguanida y un derivado de tiazolidindiona AR054238A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/093,742 US9060941B2 (en) 2002-09-20 2005-03-30 Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Publications (1)

Publication Number Publication Date
AR054238A1 true AR054238A1 (es) 2007-06-13

Family

ID=37073782

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20060100990A AR054238A1 (es) 2005-03-30 2006-03-15 Composicion farmaceutica que contiene una biguanida y un derivado de tiazolidindiona

Country Status (25)

Country Link
US (1) US9060941B2 (es)
EP (1) EP1863445B1 (es)
JP (2) JP5827781B2 (es)
KR (1) KR101401412B1 (es)
CN (1) CN101222912B (es)
AR (1) AR054238A1 (es)
AU (1) AU2006232993B2 (es)
BR (1) BRPI0609550A2 (es)
CA (1) CA2601501C (es)
CR (1) CR9355A (es)
EA (1) EA015244B1 (es)
ES (1) ES2573321T3 (es)
GE (1) GEP20104936B (es)
HK (1) HK1114337A1 (es)
IL (1) IL186308A (es)
MA (1) MA29675B1 (es)
MX (1) MX2007011824A (es)
NO (1) NO20075427L (es)
NZ (1) NZ561124A (es)
PE (1) PE20061389A1 (es)
SG (1) SG160415A1 (es)
TW (1) TWI344375B (es)
UA (1) UA91852C2 (es)
WO (1) WO2006107528A1 (es)
ZA (1) ZA200707137B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7588779B2 (en) * 2004-05-28 2009-09-15 Andrx Labs, Llc Pharmaceutical formulation containing a biguanide and an angiotensin antagonist
US20080026054A1 (en) * 2007-04-27 2008-01-31 Nectid Inc. Novel anelgesic combination
US20080031950A1 (en) * 2007-04-27 2008-02-07 Nectid Inc. Novel anelgesic combination
NZ588695A (en) * 2008-03-21 2012-11-30 Mylan Pharmaceuticals Inc Extended release forumulation containing a wax and ciprofloxacin
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
US20130251795A1 (en) * 2010-07-30 2013-09-26 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
US20120093878A1 (en) * 2010-07-30 2012-04-19 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a thiazolidinedione
CN101912375A (zh) * 2010-08-26 2010-12-15 冯岩 一种二甲双胍控释片
CN102727459A (zh) * 2011-04-15 2012-10-17 江苏豪森医药集团有限公司 一种具有第一和第二活性药物的制剂
EA201490840A1 (ru) 2011-10-21 2014-08-29 Такеда Фармасьютикал Компани Лимитед Препарат с замедленным высвобождением
EP2987489A4 (en) * 2013-04-19 2016-09-07 Takeda Pharmaceutical MEDICINAL FORMULATION WITH DELAYED RELEASE
MA39929A (fr) * 2014-11-27 2016-06-01 Arven Ilac Sanayi Ve Ticaret As Comprimé multicouche comprenant de la metformine et du pioglitazone
CA3107945A1 (en) * 2018-08-02 2020-02-06 Hospital Sant Joan De Deu Immediate release formulation of a triple combination of active pharmaceutical ingredients useful in the treatment of polycystic ovary syndrome
GB202006849D0 (en) 2020-05-08 2020-06-24 Kancera Ab New use

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US3621097A (en) * 1970-03-30 1971-11-16 Jan Marcel Didier Aron Samuel Method and compositions for treatment of mental illness
US3960949A (en) * 1971-04-02 1976-06-01 Schering Aktiengesellschaft 1,2-Biguanides
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4080472A (en) * 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
US4034758A (en) * 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4058122A (en) * 1976-02-02 1977-11-15 Alza Corporation Osmotic system with laminated wall formed of different materials
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
US4220648A (en) * 1979-01-22 1980-09-02 The Upjohn Company Antidiabetic 1,2-dihydro-2-oxo-6-neopentyl-nicotinic acids
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
CA1266827A (en) 1984-06-20 1990-03-20 Merck & Co., Inc. Controlled porosity osmotic pump
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
GB8618811D0 (en) * 1986-08-01 1986-09-10 Approved Prescription Services Sustained release ibuprofen formulation
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
FR2611500B1 (fr) 1987-03-06 1990-05-04 Lipha Emploi de derives du biguanide dans la preparation de medicaments
US4891223A (en) * 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US4857337A (en) * 1988-05-24 1989-08-15 American Home Products Corp. (Del) Enteric coated aspirin tablets
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
DD295760A5 (de) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
IE69174B1 (en) 1989-01-31 1996-08-07 Int Pharma Agentur A system for the controlled release of active agents and a process for its preparation
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
ES2101866T3 (es) 1991-08-26 1997-07-16 Upjohn Co Producto alimentario liquido que contiene acido 3-guanidinopropionico.
US5200194A (en) * 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
US5294770A (en) * 1992-01-14 1994-03-15 Alza Corporation Laser tablet treatment system with dual access to tablet
US5376771A (en) * 1992-07-07 1994-12-27 Merck & Co., Inc. High speed process for preparing orifices in pharmaceutical dosage forms
CA2124568C (en) * 1992-10-09 2003-11-11 Yoshiaki Yano Method for producing microgranulated particle
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US5917052A (en) 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
AUPM897594A0 (en) * 1994-10-25 1994-11-17 Daratech Pty Ltd Controlled release container
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
US5658474A (en) * 1994-12-16 1997-08-19 Alza Corporation Method and apparatus for forming dispenser delivery ports
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
RU2158607C2 (ru) 1995-07-03 2000-11-10 Санкио Компани Лимитед Лечение артериосклероза и ксантомы
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
JP4083818B2 (ja) 1997-06-06 2008-04-30 ディポメド，インコーポレイティド 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
WO1999029314A1 (en) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Novel salts of metformin and method
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
EA003101B1 (ru) * 1998-03-19 2002-12-26 Бристол-Майерз Сквибб Компани Двухфазная система доставки с регулируемым высвобождением для фармацевтических средств с высокой растворимостью и способ лечения диабета с помощью этой системы
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
WO1999055320A1 (en) 1998-04-29 1999-11-04 Sumitomo Pharmaceuticals Co., Ltd. Oral formulation comprising biguanide and an organic acid
US6191162B1 (en) * 1998-05-28 2001-02-20 Medical Research Institute Method of reducing serum glucose levels
WO2000000195A1 (en) * 1998-06-30 2000-01-06 Takeda Chemical Industries, Ltd. Pharmaceutical composition for the treatment of diabetes
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
CZ20011629A3 (cs) 1998-11-12 2001-12-12 Smithkline Beecham Plc Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
KR100752000B1 (ko) 1999-05-27 2007-08-28 아쿠스피어 인코포레이티드. 다공성 약물 매트릭스의 제조방법
AU1403501A (en) 1999-11-16 2001-05-30 Smithkline Beecham Plc Novel composition and use
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
CA2394968A1 (en) * 1999-12-16 2001-06-21 Alza Corporation Dosage forms having a barrier layer to laser ablation
BR0007360A (pt) 1999-12-23 2001-08-14 Johnson & Johnson Composição de liberação controlada
MXPA02006335A (es) 1999-12-23 2002-12-13 Pfizer Prod Inc Forma de dosificacion de farmaco en capas impulsada por hidrogel.
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
SE0001151D0 (sv) 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
US6524621B2 (en) * 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6296874B1 (en) * 2000-05-01 2001-10-02 Aeropharm Technology Incorporated Core formulation comprising troglitazone and abiguanide
US6780432B1 (en) 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
US6451342B2 (en) * 2000-05-01 2002-09-17 Aeropharm Technology Incorporated Core formulation comprised of troglitazone and a biguanide
US6403121B1 (en) * 2000-05-01 2002-06-11 Aeropharm Technology Incorporated Core formulation
DE10025946A1 (de) * 2000-05-26 2001-11-29 Gruenenthal Gmbh Wirkstoffkombination
US20030086972A1 (en) 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
WO2002028181A1 (en) 2000-10-02 2002-04-11 Usv Limited Sustained release pharmaceutical compositions containing metformin and method of its production
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
CA2436373A1 (en) * 2001-01-30 2002-08-08 Teijin Limited Pharmaceutical composition
JP4848558B2 (ja) 2001-05-08 2011-12-28 トーアエイヨー株式会社 塩酸メトホルミン含有速放性錠剤
US6838093B2 (en) * 2001-06-01 2005-01-04 Shire Laboratories, Inc. System for osmotic delivery of pharmaceutically active agents
WO2003004009A1 (en) 2001-07-02 2003-01-16 Geneva Pharmaceuticals, Inc. Pharmaceutical composition
US6703045B2 (en) * 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
AU2002341959A1 (en) * 2001-10-04 2003-04-14 Case Western Reserve University Drug delivery devices and methods
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
ITFI20010230A1 (it) 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
US20030224046A1 (en) * 2002-06-03 2003-12-04 Vinay Rao Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
CN100367960C (zh) 2002-07-11 2008-02-13 武田药品工业株式会社 包衣制剂的制备方法
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
EP1539144B1 (en) 2002-09-20 2014-12-24 Andrx Labs Llc Multistage formulation containing a biguanide and a thiazolidinedione derivative
IN192749B (es) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
KR101114808B1 (ko) * 2003-01-29 2012-02-15 다케다 야쿠힌 고교 가부시키가이샤 피복 제제의 제조법
BRPI0417829A (pt) 2003-12-19 2007-04-10 Omega Bio Pharma Ip3 Ltd composições e processos para tratamento da diabetes
CN1968692A (zh) 2004-05-03 2007-05-23 杜克大学 影响体重减轻的组合物
CN1327840C (zh) 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用

Also Published As

Publication number Publication date
CN101222912B (zh) 2012-10-03
EP1863445B1 (en) 2016-05-11
CA2601501A1 (en) 2006-10-12
NZ561124A (en) 2010-12-24
EA200702116A1 (ru) 2008-02-28
IL186308A (en) 2014-05-28
NO20075427L (no) 2007-10-25
US20050226928A1 (en) 2005-10-13
CR9355A (es) 2008-01-21
MX2007011824A (es) 2008-02-12
ZA200707137B (en) 2014-07-30
PE20061389A1 (es) 2007-01-21
JP2013209426A (ja) 2013-10-10
US9060941B2 (en) 2015-06-23
ES2573321T3 (es) 2016-06-07
CA2601501C (en) 2013-04-09
GEP20104936B (en) 2010-03-25
UA91852C2 (ru) 2010-09-10
KR20080005359A (ko) 2008-01-11
EP1863445A4 (en) 2012-08-01
AU2006232993B2 (en) 2012-01-19
TWI344375B (en) 2011-07-01
SG160415A1 (en) 2010-04-29
AU2006232993A1 (en) 2006-10-12
EP1863445A1 (en) 2007-12-12
TW200718433A (en) 2007-05-16
JP5827781B2 (ja) 2015-12-02
KR101401412B1 (ko) 2014-06-11
BRPI0609550A2 (pt) 2010-04-13
IL186308A0 (en) 2011-08-01
CN101222912A (zh) 2008-07-16
HK1114337A1 (en) 2008-10-31
JP2008534589A (ja) 2008-08-28
EA015244B1 (ru) 2011-06-30
WO2006107528A1 (en) 2006-10-12
MA29675B1 (fr) 2008-08-01

Similar Documents

Publication Publication Date Title
AR054238A1 (es) Composicion farmaceutica que contiene una biguanida y un derivado de tiazolidindiona
KR101834033B1 (ko) 주의력 결핍 장애 치료용 고체 경구 제약 조성물
CR9950A (es) Composiciones farmaceuticas solidas que contienen pregabalina
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
CR9704A (es) Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma.
PE20051127A1 (es) Comprimido multicapa de telmisartan y ramipril
CO6150127A2 (es) Formulaciones de flibanserina y metodo para fabricarlas
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
ES2282062T1 (es) Composicion farmaceutica que contiene irbesartan.
MX2009008100A (es) Preparacion solida que comprende alogliptina y pioglitazona.
CL2008000823A1 (es) Formulacion farmaceutica de liberacion inmediata que comprende dapagliflozina propilenglicol hidrato y un portador farmaceuticamente aceptable; uso para tratar diabetes, intolerancia a la glucosa, resistencia a la insulina, entre otras.
AR051099A1 (es) Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas
AR037255A1 (es) Composiciones farmaceuticas que contienen oxibutinina
AR077411A2 (es) Forma de dosificacion farmaceutica solida, con lopinavir y ritonavir, y proceso para su preparacion.
RU2016122609A (ru) Составы соединений азаиндола
AR061169A1 (es) Formulaciones farmaceuticas de fenilferina y composiciones para su absorcion en el colon
BRPI0610634A2 (pt) combinação para a terapia de hiperplasia benigna da próstata
PE20110019A1 (es) Composicion farmaceutica que contiene un sensibilizante de insulina y un secretagogo de insulina
WO2009134057A3 (ko) 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
RS52374B (en) FORMS OF MEDICINES WITH IMPROVED PHARMACOKINETIC CHARACTERISTICS
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
AR033688A1 (es) Composicion parenteral reconstituible
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
AU2014299447B2 (en) Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin

Legal Events

Date Code Title Description
FB Suspension of granting procedure